Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge in clinical oncology. Surgery is the only potentially curative treatment. However, the majority of PDAC patients present with locally advanced/unresectable or metastatic disease, where palliative multiagent chemotherapy is the f...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/12/3215 |
| _version_ | 1797461283551838208 |
|---|---|
| author | Sylvia S. W. Ng Laura A. Dawson |
| author_facet | Sylvia S. W. Ng Laura A. Dawson |
| author_sort | Sylvia S. W. Ng |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge in clinical oncology. Surgery is the only potentially curative treatment. However, the majority of PDAC patients present with locally advanced/unresectable or metastatic disease, where palliative multiagent chemotherapy is the first-line treatment with the therapeutic intent to delay progression and prolong survival. For locally advanced/unresectable pancreatic cancer patients who are treated with chemotherapy, consolidative radiotherapy in the form concurrent chemoradiation or stereotactic ablative radiotherapy improves locoregional control and pain/symptom control. To improve clinical outcomes of PDAC patients, there is a dire need for discoveries that will shed more light on the pathophysiology of the disease and lead to the development of more efficacious treatment strategies. Inflammatory cytokines are known to play a role in mediating tumor progression, chemoresistance, and radioresistance in PDAC. A PubMed search on published articles related to radiotherapy, inflammatory cytokines, and pancreatic cancer patients in the English language was performed. This article primarily focuses on reviewing the clinical literature that examines the association of inflammatory cytokines with clinical outcomes and the effects of radiotherapy on inflammatory cytokines in PDAC patients. |
| first_indexed | 2024-03-09T17:17:00Z |
| format | Article |
| id | doaj.art-2cae0715a91f40e688b5854e4cb36fd9 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T17:17:00Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-2cae0715a91f40e688b5854e4cb36fd92023-11-24T13:28:50ZengMDPI AGBiomedicines2227-90592022-12-011012321510.3390/biomedicines10123215Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal AdenocarcinomaSylvia S. W. Ng0Laura A. Dawson1Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaDepartment of Radiation Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5T 1P5, CanadaPancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge in clinical oncology. Surgery is the only potentially curative treatment. However, the majority of PDAC patients present with locally advanced/unresectable or metastatic disease, where palliative multiagent chemotherapy is the first-line treatment with the therapeutic intent to delay progression and prolong survival. For locally advanced/unresectable pancreatic cancer patients who are treated with chemotherapy, consolidative radiotherapy in the form concurrent chemoradiation or stereotactic ablative radiotherapy improves locoregional control and pain/symptom control. To improve clinical outcomes of PDAC patients, there is a dire need for discoveries that will shed more light on the pathophysiology of the disease and lead to the development of more efficacious treatment strategies. Inflammatory cytokines are known to play a role in mediating tumor progression, chemoresistance, and radioresistance in PDAC. A PubMed search on published articles related to radiotherapy, inflammatory cytokines, and pancreatic cancer patients in the English language was performed. This article primarily focuses on reviewing the clinical literature that examines the association of inflammatory cytokines with clinical outcomes and the effects of radiotherapy on inflammatory cytokines in PDAC patients.https://www.mdpi.com/2227-9059/10/12/3215pancreatic cancerstereotactic ablative radiotherapyinterleukinsinflammatory cytokinestumor–stromal interactions |
| spellingShingle | Sylvia S. W. Ng Laura A. Dawson Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma Biomedicines pancreatic cancer stereotactic ablative radiotherapy interleukins inflammatory cytokines tumor–stromal interactions |
| title | Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma |
| title_full | Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma |
| title_fullStr | Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma |
| title_short | Inflammatory Cytokines and Radiotherapy in Pancreatic Ductal Adenocarcinoma |
| title_sort | inflammatory cytokines and radiotherapy in pancreatic ductal adenocarcinoma |
| topic | pancreatic cancer stereotactic ablative radiotherapy interleukins inflammatory cytokines tumor–stromal interactions |
| url | https://www.mdpi.com/2227-9059/10/12/3215 |
| work_keys_str_mv | AT sylviaswng inflammatorycytokinesandradiotherapyinpancreaticductaladenocarcinoma AT lauraadawson inflammatorycytokinesandradiotherapyinpancreaticductaladenocarcinoma |